Articles from Saladax Biomedical, Inc.

Saladax Biomedical to Expand International Access to Drug Level Testing for Psychiatry and Oncology
Bethlehem, PA, April 07, 2026 (GLOBE NEWSWIRE) -- Saladax Biomedical, Inc., a leader in therapeutic drug monitoring (TDM) diagnostics for psychiatry and oncology, today announced a distribution agreement with Thermo Fisher Scientific to expand global access to high-quality TDM assays that support clinicians in optimizing patient outcomes. Under the agreement, Thermo Fisher will distribute Saladax therapeutic drug monitoring (TDM) tests through its established global commercial organization. The portfolio includes assays used to monitor the top prescribed antipsychotic medications such as clozapine, as well as widely used chemotherapy agents, where drug exposure can vary significantly between patients. In these cases, monitoring is essential to ensure patients are receiving the proper dosage of medication.
By Saladax Biomedical, Inc. · Via GlobeNewswire · April 7, 2026
Saladax Biomedical Inc. Appoints Regulatory and Quality Expert Ms. Stacie Geffner-Atiya as Director of Regulatory and Quality
Bethlehem, PA, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Saladax Biomedical, Inc., a leader in innovative therapeutic drug monitoring (TDM) solutions, is pleased to announce the appointment of Ms. Stacie Geffner-Atiya as Director of Regulatory and Quality. With over 20 years of regulatory experience diagnostics (IVDs) and medical devices, Ms. Geffner-Atiya brings a wealth of expertise in navigating complex global regulatory landscapes. Ms. Geffner-Atiya has successfully led regulatory strategies across large blue-chip corporations and pioneering start-ups, securing clearances under IVDRR, 510(k) submissions, and PMAs. Her extensive experience spans a diverse portfolio of medical products, including point-of-care glucose meters, endoscopes, infusion pumps, and insulin pumps.
By Saladax Biomedical, Inc. · Via GlobeNewswire · February 18, 2025
Saladax Biomedical Inc. Welcomes Dr. Sepideh Fanaei as Country Manager for DACH Region, Supporting EU Expansion and Revenue Growth
Bethlehem, PA, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Saladax Biomedical, Inc. is thrilled to announce the appointment of Dr. Sepideh Fanaei as Country Manager for the DACH region, which encompasses Germany, Austria, and Switzerland. This new role signifies a critical step in Saladax’s European expansion strategy, which aims to advance the company’s growth in the EU healthcare market.
By Saladax Biomedical, Inc. · Via GlobeNewswire · November 21, 2024
Health Canada Approves Saladax’s 5-Fluorouracil Chemotherapy Therapeutic Drug Monitoring (TDM) Test
Bethlehem, PA, May 14, 2024 (GLOBE NEWSWIRE) -- Saladax Biomedical, Inc. (Saladax) is pleased to announce that Health Canada has approved Saladax’s 5-Fluorouracil (My5-FU) Assay for sale in Canada in a rapid six days. This approval recognizes the vital importance of implementing updated guidelines and using 5-Fluorouracil (5-FU) TDM to ensure patients undergoing cancer treatment with this chemotherapy agent get the proper dose.
By Saladax Biomedical, Inc. · Via GlobeNewswire · May 14, 2024
Saladax Biomedical, Inc. Acquires Intellectual Property Portfolio for Antipsychotic Drug Tests
Saladax Biomedical, Inc. (Saladax) is pleased to announce that it has acquired a patent portfolio for antipsychotic drug testing from Janssen Pharmaceutica NV. This intellectual property (IP) portfolio includes 17 patent families and has resulted in 33 U.S. patents and 296 patents in ex-U.S. countries. This IP, along with the current Saladax IP, covers the major antipsychotic drugs that are prescribed worldwide and places Saladax in a premier position in the antipsychotic drug testing field.
By Saladax Biomedical, Inc. · Via Business Wire · April 5, 2022
Saladax Biomedical, Inc. Announces Global Distribution Agreement With Beckman Coulter, Inc. for Antipsychotic Drug Tests
Saladax Biomedical, Inc. (Saladax) is pleased to announce the signing of a global distribution agreement with Beckman Coulter, Inc. to distribute the MyCare™ Psychiatry Laboratory Assays. The MyCare™ Psychiatry Laboratory Assays measure drug levels of the antipsychotic drugs prescribed to treat patients with serious mental illness (SMI), such as such as Schizophrenia and Bipolar Disorder.
By Saladax Biomedical, Inc. · Via Business Wire · March 15, 2022
Saladax Biomedical Announces Salvatore J. Salamone, Ph.D. Received the Prestigious Dr. C.E. Pippenger Award
Salvatore J. Salamone, Ph.D. received the prestigious Dr. C.E. Pippenger Award at the 2021 International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) annual meeting in Rome, Italy. This award is given to individuals who have made outstanding contributions to the field of Therapeutic Drug Monitoring (TDM). TDM is a field of medical science that seeks to ensure that patients receive a personalized dose of drugs to achieve an optimum therapeutic result. Unfortunately, many medications, such as anticancer, antibiotics, and antifungal treatments, have severe toxicities when overdosed and are ineffective when underdosed. TDM seeks to ensure that the patient receives enough drug to treat the condition but not too much to cause toxicities and potentially death.
By Saladax Biomedical, Inc. · Via Business Wire · September 23, 2021